homepage-top-section

The trial’s top-line data from 203 participants demonstrate that severe or critical Covid-19 patients treated with SACCOVID witnessed speedy recovery and a significant reduction in disease progression to

The deal also allows Inflazome to secure additional contingent payments based on the achievement of certain predetermined milestones. Based in Dublin, Inflazome is engaged in the development of

The vaccine candidate is being developed using Sanofi’s recombinant protein-based technology and GSK’s advanced adjuvant technology. Sanofi’s protein-based technology is currently used to produce an influenza vaccine. Both

Situated at the company’s R&D headquarters in Boston, the new facility offers end-to-end research and development services to advance the development of next-generation cell therapies. The new R&D

Merck and Seattle Genetics have entered into two strategic oncology collaborations to commercialise Seattle Genetics’ antibody-drug conjugate (ADC) ladiratuzumab vedotin and small-molecule tyrosine kinase inhibitor (TKI) Tukysa (tucatinib).

Ibrutinib, a once-a-day drug that is administered orally, inhibits the first-in-class Bruton’s tyrosine kinase (BTK) that sends crucial signals to B cells to mature and produce antibodies, said

Gavreto, a once-daily and oral precision therapy, will help selectively target RET alterations such as fusions and mutations irrespective of the tissue of origin. Roche’s wholly-owned member Genentech

The company has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application of brequinar to treat Covid-19. Brequinar is an

Based in Boston of Massachusetts, Akcea Therapeutics is engaged in the development and commercialisation of medicines for the treatment of patients with serious and rare diseases. Under the